CHRS Coherus BioSciences Inc.

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.

The panel discussion will be accessible via webcast through a link on the Investor Events and Presentations section of the Coherus website: .

Coherus Contact Information:

For Investors:

Jodi Sievers

VP, Investor Relations & Corporate Communications



EN
27/11/2024

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Report Third Quarter 2025 Financial Results on Nov...

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of the live conference call. Con...

13h / 53m 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific TimeJefferies Global Healthcare Conference in London, England on Tuesday, November 18, 2025, at 10:30 a.m. Greenwich Mean Time / 5:30 a.m. Eastern TimeBaird Biotech Discovery Series takes pl...

October 23, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Announces Poster Presentation at the 40th Annual Meet...

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor, Maryland. Abstract # 640: CHS-114, an ...

October 3, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight TimeH.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Wednesday, September 10, 2025, at 11:00 a.m. Eastern Daylight Time / 8:00 a.m. Pacific Daylig...

September 3, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology Reports Second Quarter 2025 Financial Results and Pro...

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update – LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent b...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch